Krane Funds Advisors LLC I Mab Transaction History

Krane Funds Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$8.27 - $18.43 $156,807 - $349,451	-18,961 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$12.54 - $46.93 $23,035 - $86,210	1,837 Added 10.73%	18,961 $308,000
Q4 2021 Feb 10, 2022	SELL	$45.28 - $74.5 $83,949 - $138,123	-1,854 Reduced 9.77%	17,124 $812,000
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $37,510 - $55,386	-656 Reduced 3.34%	18,978 $1.38 Million
Q2 2021 Aug 12, 2021	BUY	$47.86 - $83.95 $930,063 - $1.63 Million	19,433 Added 9668.16%	19,634 $1.65 Million
Q4 2020 Feb 11, 2021	BUY	$32.94 - $47.15 $6,620 - $9,477	201 New	201 $9,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $80.6M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Krane Funds Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Krane Funds Advisors LLC with notifications on news.